Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Personal Products Industry Analysis

UpdatedJun 25, 2026
DataAggregated Company Financials
Companies108
  • 7D2.4%
  • 3M9.5%
  • 1Y-16.3%
  • YTD-9.9%

Over the last 7 days, the Personal Products industry has dropped 3.0%, driven by Estée Lauder Companies declining 4.4%. On the other hand SL Science Holding is actually up 74%. However, the industry is down 17% over the past year. Looking forward, earnings are forecast to grow by 33% annually.

Industry Valuation and Performance

Has the U.S. Personal Products Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 25 Jun 2026US$83.1bUS$48.3bUS$693.8m18.4x119.8x1.7x
Sat, 23 May 2026US$77.1bUS$48.4bUS$752.9m15.7x102.4x1.6x
Mon, 20 Apr 2026US$78.6bUS$48.1bUS$614.6m22.3x127.9x1.6x
Wed, 18 Mar 2026US$82.7bUS$48.2bUS$678.5m22x121.9x1.7x
Fri, 13 Feb 2026US$92.3bUS$48.1bUS$797.0m21.3x115.8x1.9x
Sun, 11 Jan 2026US$92.7bUS$47.6bUS$350.3m21.4x264.7x1.9x
Tue, 09 Dec 2025US$89.9bUS$47.6bUS$351.1m22.4x256.2x1.9x
Thu, 06 Nov 2025US$86.4bUS$47.6bUS$505.3m21.8x170.9x1.8x
Sat, 04 Oct 2025US$88.2bUS$47.7bUS$307.3m20.4x287.1x1.9x
Mon, 01 Sep 2025US$100.8bUS$47.6bUS$303.5m22.4x332.1x2.1x
Wed, 30 Jul 2025US$103.6bUS$48.1bUS$108.9m22.3x951.2x2.2x
Fri, 27 Jun 2025US$96.4bUS$48.0bUS$109.4m17.6x881.2x2x
Sun, 25 May 2025US$93.8bUS$48.0bUS$113.1m17.4x830.1x2x
Tue, 22 Apr 2025US$84.4bUS$48.7bUS$556.6m21.2x151.7x1.7x
Thu, 20 Mar 2025US$91.6bUS$48.6bUS$349.8m29.6x261.9x1.9x
Sat, 15 Feb 2025US$90.7bUS$49.0bUS$330.9m23.9x274x1.9x
Mon, 13 Jan 2025US$94.9bUS$49.3bUS$1.5b24.9x64.3x1.9x
Wed, 11 Dec 2024US$105.7bUS$49.3bUS$1.5b31.6x71.5x2.1x
Fri, 08 Nov 2024US$94.5bUS$49.4bUS$1.5b26.8x62.8x1.9x
Sun, 06 Oct 2024US$108.0bUS$49.5bUS$1.6b26.8x66.8x2.2x
Tue, 03 Sep 2024US$109.7bUS$49.5bUS$1.6b22.1x66.9x2.2x
Thu, 01 Aug 2024US$107.6bUS$48.9bUS$2.4b22.6x44.6x2.2x
Sat, 29 Jun 2024US$112.9bUS$49.0bUS$2.4b21.3x46.6x2.3x
Mon, 27 May 2024US$118.1bUS$49.0bUS$2.4b21.2x48.7x2.4x
Wed, 24 Apr 2024US$128.1bUS$48.8bUS$2.5b25.1x50.5x2.6x
Fri, 22 Mar 2024US$131.9bUS$48.7bUS$2.5b24.2x52.8x2.7x
Sun, 18 Feb 2024US$127.8bUS$49.2bUS$2.5b29.8x51x2.6x
Tue, 16 Jan 2024US$126.4bUS$49.9bUS$2.6b26.7x47.8x2.5x
Thu, 14 Dec 2023US$122.7bUS$49.9bUS$2.6b27.1x46.6x2.5x
Sat, 11 Nov 2023US$106.5bUS$49.9bUS$2.7b25.2x39.6x2.1x
Mon, 09 Oct 2023US$120.9bUS$50.0bUS$3.3b23.8x36.9x2.4x
Wed, 06 Sep 2023US$135.5bUS$50.0bUS$3.3b20.4x41.3x2.7x
Fri, 04 Aug 2023US$144.7bUS$49.9bUS$3.1b25.6x46.6x2.9x
Sun, 02 Jul 2023US$154.2bUS$49.3bUS$3.1b22.6x49.2x3.1x
Price to Earnings Ratio

49.2x


Total Market Cap: US$154.2bTotal Earnings: US$3.1bTotal Revenue: US$49.3bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Personal Products Industry Price to Earnings3Y Average 172.5x202420252026
Current Industry PE
  • Investors are pessimistic on the American Personal Products industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 118x which is lower than its 3-year average PE of 172x.
  • The 3-year average PS ratio of 2.2x is higher than the industry's current PS ratio of 1.7x.
Past Earnings Growth
  • The earnings for companies in the Personal Products industry have declined 40% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the U.S. Consumer Staples industry?

US Market-2.47%
Consumer Staples1.44%
Personal Products2.35%
Personal Products2.35%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
KVUE KenvueUS$18.804.4%
+US$1.5b		-11.2%PE22.3x
BRBR BellRing BrandsUS$11.9131.3%
+US$330.2m		-79.7%PE8.8x
EL Estée Lauder CompaniesUS$83.271.0%
+US$293.1m		7.4%PS2x
EPC Edgewell Personal CareUS$26.5817.8%
+US$185.2m		12.2%PS0.5x
IPAR InterparfumsUS$104.255.2%
+US$165.3m		-21.5%PE19.7x

Latest News

BRBR
US$11.91
BellRing Brands
7D
31.3%
1Y
-79.7%
EPC
US$26.58
Edgewell Personal Care
7D
17.8%
1Y
12.2%
ELF
US$64.54
e.l.f. Beauty
7D
3.6%
1Y
-48.5%
EL
US$83.27
Estée Lauder Companies
7D
1.0%
1Y
7.4%
IPAR
US$104.25
Interparfums
7D
5.2%
1Y
-21.5%
Analysis Article • Jun 19

Interparfums (IPAR) Stock Could Be 9.4% Undervalued After Institutional Buying

Interparfums (IPAR) is back in focus after recent data showed institutional investors now hold 66.49% of the company, with largest shareholder Chuck Royce significantly increasing his position last quarter. See our latest analysis for Interparfums. Interparfums’ recent 1 month share price return of 9.77% and 3 month share price return of 10.15%, taking the stock to US$99.09, contrast with a 1 year total shareholder return that declined 22.5%. This suggests improving short term momentum after...
HLF
US$12.47
Herbalife
7D
7.3%
1Y
51.3%
Narrative Update • Jun 18

HLF: Execution On 2026 Guidance And Margins Will Drive Stock Rebound

Analysts have lifted their price target on Herbalife to about $18.33 from $17.50, citing updated assumptions around discount rates, expected revenue growth, profit margins, and future P/E multiples reflected in recent research. Analyst Commentary Recent research on Herbalife highlights a mix of optimism around execution and valuation, alongside ongoing caution about the company’s ability to sustain and convert growth assumptions into consistent earnings.
AXIL
US$5.92
AXIL Brands
7D
-6.8%
1Y
7.8%
ODD
US$13.07
Oddity Tech
7D
13.1%
1Y
-82.3%
Narrative Update • Jun 17

ODD: Advertising Disruptions And Rising Acquisition Costs Will Pressure Shares

Oddity Tech's analyst fair value estimate has been reduced from $40.00 to $8.00. This reflects a broad reset in Street price targets as analysts factor in higher discount rates, much lower modeled revenue growth and profit margins, and a sharply higher future P/E multiple after recent advertising and earnings challenges.
WALD
US$1.53
Waldencast
7D
-7.8%
1Y
-43.3%
Narrative Update • Jun 15

WALD: Obagi Sale And Injectables Launch Will Support Future Upside

Analysts have lifted their price target on Waldencast stock to $3.00 from $2.50, citing the agreed sale of the Obagi skin care and aesthetics business for up to $460m and the view that current valuation does not fully reflect the strength of Obagi, Milk and the upcoming Saypha injectables launch. Analyst Commentary Bullish analysts see the agreed sale of the Obagi skin care and aesthetics business and the ongoing investment in Saypha injectables as key supports for the recent reset to a $3.00 price target.
OLPX
US$2.04
Olaplex Holdings
7D
-0.5%
1Y
34.2%
Narrative Update • Jun 09

OLPX: Henkel Cash Deal And Mixed Revisions Will Test Earnings Durability

Analysts have lifted their average price target on Olaplex Holdings stock to $2.00 from about $1.72, reflecting updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples drawn from recent research. Analyst Commentary Recent research on Olaplex reflects a mix of higher price targets and more cautious stances, with several firms revisiting their assumptions on discount rates, revenue growth, profit margins, and future P/E multiples.
KVUE
US$18.80
Kenvue
7D
4.4%
1Y
-11.2%
Narrative Update • Jun 08

KVUE: Future Returns Will Reflect Merger Progress And Legal Earnings Balance

Analysts slightly lifted their fair value estimate for Kenvue to $19.50, a modest move supported by small tweaks to discount rate, revenue growth, profit margin and future P/E assumptions, even as recent Street research from Citi, Barclays and UBS reflects more cautious price targets. Analyst Commentary Recent price target trims of around $1 from several firms signal that the Street is fine tuning expectations rather than making a wholesale shift in its view on Kenvue.
MED
US$10.36
Medifast
7D
-7.9%
1Y
-21.0%
Narrative Update • Jun 06

MED: Leadership Transition And Margin Outlook Will Shape Balanced Future Profile

Analysts have modestly adjusted their price target on Medifast, reflecting updated views on the discount rate, expected profit margins near 8.1%, and an anticipated P/E around 9.7x, which together suggest a slightly different risk and valuation profile for the stock. What's in the News The board has appointed Nicholas Johnson as Chief Executive Officer, effective June 1, 2026.
BHST
US$3.26
BioHarvest Sciences
7D
-3.6%
1Y
-52.3%
UPXI
US$0.79
Upexi
7D
-15.0%
1Y
-76.3%
DSY
US$2.89
Big Tree Cloud Holdings
7D
-27.6%
1Y
-89.4%